Page 2 - Hematology Development News Today : Breaking News,

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Published: May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023

Source: marketscreener.com

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Published: May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent

Source: finanznachrichten.de

Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Published: May 11, 2023

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III... | May 11, 2023

Source: marketscreener.com

Novartis Pharma AG: Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Published: May 11, 2023

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial

Source: finanznachrichten.de

Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS

Published: May 2, 2023

BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.

Source: empr.com

Page 2 - Hematology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Hematology Development Today - Breaking & Trending Today

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Novartis Pharma AG: Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS

Page 2 - Hematology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Hematology Development Today - Breaking & Trending Today

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl&#xAE; (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Novartis Pharma AG: Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)